Harbour BioMed appoints new CSO and legal head
Harbour BioMed (HKEX: 02142) has appointed Michael Patten as chief strategy officer, responsible for overseeing global corporate development and growth strategy. He will also lead the company's global alliance efforts, focusing on expanding its presence in key markets outside China.
Mr Patten, who will be based in the USA, joins the biopharmaceutical company following a career at Bristol Myers Squibb (NYSE: BMY), where he held multiple leadership roles, most recently managing strategic equity investments across the life sciences sector.
The firm has also named Ian Liu as global head of legal. Mr Liu brings experience from his tenures at law firms and in corporate legal affairs, including head of legal and governmental affairs at Simcere Pharmaceutical (HKG: 2096).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze